FEATURED

FDA Accepts Biologics License Application for Duchenne Muscular Dystrophy Cardiomyopathy Treatment

  • All
  • Education
  • Events
  • Press Releases
See more news
See more press releases

Social media

nspharmainc NS Pharma @nspharmainc ·
23h

Today we celebrate International Children’s Day, honoring the strength, courage & potential of children everywhere.

At #NSPharma, we’re driven by a commitment to improve the lives of children & families affected by rare diseases.

#HopeInAction https://x.com/NSPharmaInc/status/1991522448487944490/photo/1

nspharmainc NS Pharma @nspharmainc ·
19 Nov

Did you know the dystrophin gene has 79 exons?

When one is missing, Duchenne Muscular Dystrophy can occur. Exon skipping therapies “skip over” faulty exons, helping the body produce functional dystrophin.

Learn more: https://ow.ly/joG350XtYcC

#DuchenneAwareness #ExonSkipping https://x.com/NSPharmaInc/status/1991159550183907741/video/1

nspharmainc NS Pharma @nspharmainc ·
18 Nov

We’re proud to sponsor Austin’s Hope and their mission to support families impacted by Duchenne.

Join the Night of Hope Gala on Nov 22 in Marysville, OH for an evening of music, connection & giving back.

Learn more: https://austinshope.org

#AustinsHope #Duchenne #NSPharma https://x.com/NSPharmaInc/status/1990797530041290965/photo/1

nspharmainc NS Pharma @nspharmainc ·
17 Nov

Welcome Audra Lapati to #NSPharma as Area Business Manager!

With 20+ years in strategic account management across neurology, oncology & rare diseases, including roles at UCB, Takeda & Nutricia, she brings deep expertise to our team. We’re thrilled to have you!

#NewHire https://x.com/NSPharmaInc/status/1990435367749644518/photo/1

nspharmainc NS Pharma @nspharmainc ·
14 Nov

We’re excited to attend the #CureDuchenne Workshop in Boston!

This event unites families, clinicians & researchers to improve outcomes for those living with Duchenne.

📅 November 15
🕘 8:00 AM – 4:00 PM
📍The Westin Waltham

Learn more & register: https://ow.ly/kjq750XpZkL https://x.com/NSPharmaInc/status/1989348045683560634/photo/1

nspharmainc NS Pharma @nspharmainc ·
12 Nov

Leber congenital amaurosis is caused by mutations in the GUCY2D gene, disrupting retinal function.

We're partnering with Atsena Therapeutics to advance ATSN-101, an investigational #GeneTherapy aiming to restore vision.

Learn more: https://ow.ly/GCzY50XpZ2s

#LCA1 #RareDisease https://x.com/NSPharmaInc/status/1988623324562268474/photo/1

nspharmainc NS Pharma @nspharmainc ·
10 Nov

🌟 Welcome Susan Wierzbicki to our #QualityAssurance team as a Senior Auditor! 👏

With 20+ years in GCP audit management, compliance & vendor qualification, most recently at TKL Research, she brings deep expertise to #NSPharma. We’re thrilled to have you, Susan! 💙 https://x.com/NSPharmaInc/status/1987898435870032358/photo/1